Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Loracarbef concentrations in middle ear fluid.

H Kusmiesz1, S Shelton, O Brown

  • 1Department of Otorhinolaryngology University of Texas, Southwestern Medical Center, Dallas 75235.

Antimicrobial Agents and Chemotherapy
|October 1, 1990
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

HIV Screening in Acute Medical Patients Presenting with an Indicator Condition.

Irish medical journal·2025
Same author

Birth Cohort Study Identifies <i>Candida albicans</i> as a Risk Factor for Dental Caries.

Journal of dental research·2025
Same author

The provision of a trauma bed in theatre recovery and its impact on trauma theatre efficiency: experience from a high-volume trauma unit.

Annals of the Royal College of Surgeons of England·2024
Same author

Head-torso coordination in police officers wearing loaded tactical vests during running.

Gait & posture·2023
Same author

A Prospective Longitudinal Study of Early Childhood Caries Onset in Initially Caries-Free Children.

JDR clinical and translational research·2022
Same author

Fit-testing of respiratory protective equipment in the UK during the initial response to the COVID-19 pandemic.

The Journal of hospital infection·2021
Same journal

<i>In vitro</i> antibacterial activity of gepotidacin in combination with other antimicrobial agents against <i>Neisseria gonorrhoeae</i> isolates.

Antimicrobial agents and chemotherapy·2026
Same journal

Development of domain-specific probes of <i>Plasmodium falciparum</i> heat shock protein 70-1.

Antimicrobial agents and chemotherapy·2026
Same journal

Addressing therapeutic options for KPC-3-producing ST307-<i>Klebsiella pneumoniae</i>: insights from <i>in vitro</i> evolution and mutant prevention strategies.

Antimicrobial agents and chemotherapy·2026
Same journal

Indole-based hybrids target both asexual parasites and gametocytes of <i>Plasmodium falciparum</i> and synergize with lumefantrine.

Antimicrobial agents and chemotherapy·2026
Same journal

Lineage-specific loss of the type VI secretion system in <i>Acinetobacter baumannii</i> ST19 is associated with reduced accessory genome content.

Antimicrobial agents and chemotherapy·2026
Same journal

Genomic diversity and topical antimicrobial resistance in <i>Staphylococcus aureus</i> from clinical and carriage populations in the New York-New Jersey region.

Antimicrobial agents and chemotherapy·2026
See all related articles

Loracarbef effectively reaches middle ear fluid (MEF) concentrations that exceed the minimum inhibitory concentration (MIC) for common acute otitis media pathogens, especially at higher doses.

Area of Science:

  • Pharmacokinetics
  • Infectious Diseases
  • Otolaryngology

Background:

  • Acute otitis media (AOM) is a common childhood infection.
  • Effective antibiotic penetration into middle ear fluid (MEF) is crucial for treatment success.
  • Loracarbef is a widely used antibiotic for bacterial infections.

Purpose of the Study:

  • To quantify loracarbef concentrations in plasma and MEF.
  • To determine the percentage of MEF concentration relative to plasma concentration.
  • To assess if loracarbef MEF concentrations are sufficient to inhibit common AOM pathogens.

Main Methods:

  • Plasma and MEF samples were collected 2 hours post-dose.
  • Loracarbef concentrations were measured using established analytical methods.

Related Experiment Videos

  • Doses administered were 7.5 mg/kg and 15 mg/kg.
  • Minimum inhibitory concentrations (MICs) for common AOM pathogens were used as a benchmark.

    • Main Results:

    • Mean loracarbef MEF concentrations were 2.0 +/- 2.6 mg/L (48% of plasma) for the 7.5 mg/kg dose.
    • Mean loracarbef MEF concentrations were 3.9 +/- 2.6 mg/L (42% of plasma) for the 15 mg/kg dose.
    • With the 15 mg/kg dose, MEF concentrations exceeded the MIC for 90% of tested AOM pathogens in 16 of 17 specimens.

    Conclusions:

    • Loracarbef demonstrates significant penetration into middle ear fluid.
    • Higher loracarbef doses lead to increased MEF concentrations.
    • Loracarbef at a 15 mg/kg dose is likely effective against common pathogens causing acute otitis media.